Highest-materiality recent filing
VolitionRx Q1 2026 revenue $1.0M; $5M milestone potential from feline lymphoma test
Revenue of $1.0M in Q1 2026 vs $0.2M in Q1 2025; operating loss decreased 3% YoY.
VolitionRx completes 1-for-20 reverse stock split effective April 28, 2026
Stockholders approved reverse split at special meeting March 31, 2026; Board set ratio at 1:20.
NYSE American accepts VolitionRx compliance plan; shares continue trading until Aug 2027 review
Received non-compliance notice on Feb 6, 2026 for stockholders' equity deficiency (below $2M threshold).
VolitionRx FY2025 revenue up 40% to $1.7M; net loss down 14%
Full-year revenue $1.7M (+40% YoY); Q4 revenue growth 133% vs prior year.
VolitionRx issues 6.4M shares to Lind Global to satisfy $1.42M debt payments
Feb 17, 2026: issued 1,956,178 shares to Lind Global for $416,666 payment.
Received NYSE American notice on Feb 6, 2026 for failing $2M, $4M, $6M stockholders' equity thresholds due to sustained losses.
VolitionRx secures $2.0M funding from Lind Global with convertible note and warrants
Gross proceeds $2M; issues $2.4M senior secured convertible note and 7,000,350 warrants at $0.5714/share.
VolitionRx Q3 revenue up 32% to $0.6M; signs deals with Werfen and Hologic
Revenue $0.6M (+32% YoY); net loss down 8% YoY; operating expenses down 10% YoY.
Amendment allows Over-Allotment Option to be exercised separately for shares and/or warrants, not combined.
VolitionRx raises $6M in underwritten offering; only $0.3M cash pre-offering
Gross proceeds $6.0M from 11.55M units at $0.52; net ~$5.4M after underwriting discounts and expenses.
On May 12, 2026, Mickie Henshall notified the Board of Directors (the “Board”) of VolitionRx Limited (the “Company”) of her decision not to stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).
Max materiality 0.80 · Median 0.60 · Most common event other_material